GODREJAGRO - Godrej Agrovet Limited Share Price

In the Q4 FY '26 earnings call held on May 4, 2026, Godrej Agrovet management provided an optimistic outlook for FY '27. The management aims for overall double-digit revenue growth at the consolidated level and mid-teens profit before tax (PBT) growth. Specific business segment targets include:

1. Animal Nutrition: Expected double-digit revenue growth driven by volume. Recent quarterly volumes increased by 15% year-on-year, particularly in cattle feed, which grew by 24%.

2. Crop Care: Anticipated recovery, particularly from Q2 FY '27 onwards, with substantial growth in both revenue and PBT. The management is looking to introduce new products and improve the business mix.

3. Oil Palm: Projecting another year of double-digit volume growth, bolstered by record area expansion and improved oil extraction ratios.

4. Godrej Foods: Planning for continued double-digit growth in the value-added portfolio, especially focusing on branded offerings.

5. Astec LifeSciences: Positive growth expected in both CDMO and enterprise segments. Overall, a 15% growth in the top line is anticipated, with EBITDA margin maintenance.

Management also emphasized their focus on disciplined execution, margin expansion, and strong cash flow generation, with working capital reduction potentially yielding INR 100-125 crores in surplus cash after capex spending of approximately INR 400 crores.

Notably, the future remains contingent on geopolitical factors and weather patterns impacting crop yields and raw material availability. Overall, Godrej Agrovet is positioning itself for sustainable growth across various business segments while enhancing shareholder value.

Here are the major questions from the Q&A section of the Godrej Agrovet Limited earnings transcript along with detailed answers crafted from a first-person perspective:

Question 1: "From the standpoint of FY '27, what kind of revenue growth and profitability might we expect for the year ahead?"
Answer: "For FY '27, we are aiming for early double-digit revenue growth at the consolidated level. We're also targeting mid-strong double-digit, mid-teens PBT growth. The Animal Nutrition business will pursue double-digit revenue growth driven by volume, and we're optimistic about recovery in Crop Care from Q2 onwards."

Question 2: "On the palm oil business, how do you see the trajectory of palm oil prices, and how does this interact with your guidance?"
Answer: "Currently, the outlook for palm oil is uncertain due to the recent Middle East situation. We expect to review prices quarterly rather than annually. If the war persists, it could have mixed impacts on our operations, but we're cautiously optimistic about stability in the near term."

Question 3: "What is the growth expectation for Astec LifeSciences given the recent management restructuring?"
Answer: "We forecast around 15% growth for Astec's top line, with CDMO possibly outpacing that. We've made strategic changes to leverage our chemical expertise, aiming for enhanced performance in both CDMO and enterprise segments moving forward."

Question 4: "Can you explain the impact of the expected below-normal monsoons on your segments?"
Answer: "While lower rainfall could affect our Crop Care business, we've noted that geographic variance might mitigate this. Our oil palm segment could remain unaffected in the short term, and our Animal Nutrition business will likely see a strong response depending on milk yields."

Question 5: "Could you provide outlook on capex and working capital for FY '27, and how will you use any surplus cash generated?"
Answer: "We estimate a capex of around INR 400 crores planned for FY '27, aiming for a cash surplus of about INR 100-125 crores afterwards. This cash will primarily support growth in high-potential segments, maintaining our disciplined approach to capital allocation."

These succinct answers capture the essence of the management's responses while keeping relevant details like growth percentages and capital expenditure estimates intact.